French regulators cite contamination, other issues at factory of Indian API maker Dhanuka Labs

French regulators have slammed Indian API maker Dhanuka Labs after inspectors found a risk for product contamination and other issues at its Gurgaon, Haryana, plant, following a similar rebuke in 2016. (EMA)

The French National Agency for Medicines and Health Products Safety issued a warning letter to Indian API maker Dhanuka Labs after inspectors found a risk for product contamination and other issues at its Gurgaon, Haryana, plant.

In its letter posted on the EudraGMPD website, the French regulatory agency said an inspection conducted in late March found a total of 24 deficiencies at the factory that produces APIs for antibiotics, including cephalosporin.

Of the issues, one was critical in that inspectors found multiple risks of contamination. Other problems listed as major included water-quality control, insufficient maintenance of the plant, material storage issues and validation problems.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

In its letter, the agency recommended a recall be issued of batches already released. Additionally, it called for the plant to be prohibited from supplying APIs until the issues at the facility are resolved.

The plant was cited for similar problems in 2016 following an inspection conducted by Croatia’s Halmed agency, which found critical issues with the plant's quality-assurance protocols, documentation and materials management.

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.